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Abstract 14 
Background:  15 
Autism Spectrum Disorder (ASD) is a common lifelong condition affecting 1 in 100 people. ASD 16 
affects how a person relates to others and the world around them. Difficulty responding to sensory 17 
information (noise, touch, movement, taste, sight) is common, and might include feeling 18 
overwhelmed or distressed by loud or constant low-level noise (e.g. in the classroom). Affected 19 
children may also show little or no response to these sensory cues. These ‘sensory processing 20 
difficulties’ are associated with behaviour and socialisation problems, and affect education, 21 
relationships, and participation in daily life. Sensory Integration Therapy (SIT) is a face-to-face 22 
therapy or treatment, provided by trained occupational therapists who use play -based sensory-23 
motor activities and the just-right challenge to influence the way the child responds to sensation, 24 
reducing distress, and improving motor skills,  adaptive responses, concentration and interaction 25 
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with others. With limited research into SIT, this protocol describes in detail how the intervention will 1 
be defined and evaluated. 2 
 3 
Methods:  4 
Two-arm pragmatic individually 1:1 Randomised Controlled Trial (RCT) with internal pilot of SIT 5 
versus Usual Care (UC) for primary school aged children (4 to 11 years) with ASD and Sensory 6 
Processing (SP) difficulties. 216 children will be recruited from multiple sources. Therapy will be 7 
delivered in clinics meeting full fidelity criteria for manualised SIT over 26 weeks (face-to-face 8 
sessions: 2 per week for 10 weeks, 2 per month for 2 months; Telephone call: 1 per month for 2 9 
months). Follow up assessments will be completed at 6 and 12 months post randomisation. Prior to 10 
recruitment: therapists will be invited to participate in focus groups/interviews to explore what is 11 
delivered as usual care in trial regions; carers will be invited to complete an online survey to map out 12 
their experience of services. Following recruitment: carers will be given diaries to record their 13 
contact with services. Following intervention, carer and therapist interviews will be completed. 14 
 15 
Discussion:  16 
Results of this trial will provide high quality evidence on the clinical and cost-effectiveness of SIT 17 
aimed at improving behavioural, functional, social, educational and well-being outcomes for children 18 
and well-being outcomes for carers and families.   19 
 20 
Trial registration:  21 
ISRCTN14716440. Registered 08/11/2016. http://www.isrctn.com/ISRCTN14716440 22 
 23 
Keywords: 24 
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 2 
Background 3 
Difficulties in sensory processing (SP) are common in Autism Spectrum Disorders (ASD) with 4 
prevalence estimates of 90-95%(1)(2)(3). Such difficulties relate to hyper or hypo-reactivity to 5 
sensory input and may occur due to impaired regulation of central nervous system arousal(4). This 6 
hyper-reactivity may be associated with challenging behaviour such as aggression (e.g., to 7 
communicate discomfort with noise/touch), or additional “safe space” needs in the home(5). 8 
Impaired sensory processing may also be associated with poor motor control impacting on 9 
participation in daily life. There is substantial potential burden related to sensory processing 10 
difficulties for children with ASD, their carers and families, and also to the NHS (National Health 11 
Service) in terms of treating associated difficulties such as behaviour problems(6). Sensory 12 
processing difficulties also pose significant challenges in mainstream education settings. It is 13 
plausible that interventions targeting sensory processing difficulties could result in improvements 14 
across behavioural, social, and educational dimensions. 15 
A variety of potential play-based therapies have been proposed, with a clear distinction between 16 
Sensory-Based Interventions (SBIs) and Sensory Integration Therapy (SIT). SBIs are usually sensory 17 
strategies applied to the child or made available to the child for regulation of their reactivity within 18 
the home or school environment. Current research into the effectiveness of these SBIs is insufficient 19 
to recommend their use, especially if they are not individualised to the child(7). 20 
 SIT is a clinic-based approach that focuses on the therapist-child relationship and uses play-based 21 
sensory motor activities designed to improve sensation processing and integration(8). SIT shows 22 
some promise as a potential therapy(9)(10)(11) but underpinning evidence is limited. In particular 23 
some of the reported evaluations involved interventions either poorly defining criteria for SIT fidelity 24 
or indeed not meeting them at all(7). Although SIT is currently offered by the NHS in some regions, 25 
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the National Institute for Health and Care Excellence (NICE) reported that available evidence was of 1 
low quality and, therefore, insufficient to recommend treatment(12). 2 
The key aims of this trial are to: (i) to evaluate the effectiveness of manualised Ayres Sensory 3 
Integration® therapy (SIT) on behavioural problems and adaptive skills, socialisation, carer stress, 4 
quality of life, and cost; (ii) describe current usual care in trial regions and clearly differentiate this 5 
from the proposed intervention (SIT).  6 
 7 
Methods 8 
Primary objective 9 
To determine the impact of SIT on irritability and agitation, as measured by the corresponding sub-10 
scale of the Aberrant Behaviour Checklist (ABC)(13)(14). 11 
 12 
Secondary objectives 13 
To evaluate: 14 
i. effectiveness of SIT for additional behaviour problems such as hyperactivity/non-15 
compliance, lethargy/social withdrawal, stereotypic behaviour, inappropriate speech 16 
ii. the impact of SIT on adaptive skills, functioning, and socialisation  17 
iii. sensory processing scores post-intervention (i.e. at six months) as a potential mediator of 18 
any association observed between SIT and the primary outcome at 12 months  19 
iv. age, severity of SP difficulties, adaptive behaviour, socialisation and comorbid conditions as 20 
potential moderators of any association between SIT and irritability/agitation, adaptive 21 
functioning (child) and carer stress  22 
v. the impact of the intervention on carer stress and Quality of Life (QoL) 23 
vi. cost-effectiveness of the intervention, including direct intervention costs, health, social care, 24 
education services, carer expenses and lost productivity costs 25 
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vii. fidelity, recruitment, acceptability, adherence, adverse effects and contamination in a 1 
process evaluation conducted alongside the main trial. An internal pilot with specific 2 
progression criteria will assess the feasibility of proposed recruitment and trial retention 3 
rates and whether usual care (UC) differs from expected provision of SIT.  4 
 5 
Study design 6 
A two arm individually randomised (1:1 ratio) effectiveness trial of SIT for children with ASD and SP 7 
difficulties in mainstream primary education (aged 4 to 11 years old). The comparator will be Usual 8 
Care (UC). Manualised SIT will be delivered in clinics meeting full fidelity criteria (structural 9 
equipment elements)(15). The target is to recruit 216 children. Those allocated to the intervention 10 
group will continue to receive any care currently being received provided it does not contravene the 11 
eligibility criteria.  12 
A process evaluation following Medical Research Council (MRC) guidance(16) will examine 13 
contamination, fidelity of intervention delivery, adherence and any adverse effects. It will also 14 
include assessment of recruitment, retention, adherence and intervention reach. Therapist and carer 15 
interviews will explore: barriers/facilitators, adherence, therapeutic relationship, mechanisms of 16 
change, SP deficit, engagement in activities and contamination.  17 
 18 
Eligibility criteria 19 
Participants must: 20 
i. have a diagnosis of ASD (as documented on medical and/or educational records), OR have 21 
probable/likely ASD (defined as currently being assessed within the local ASD pathway);  22 
ii. aged 4-11 years at the start of the trial; 23 
iii. plan to remain in mainstream primary education until the primary outcome time-point (6-24 
months post-randomisation, and end of intervention for SIT arm); 25 
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iv. have definite or probable SP difficulties defined as: (a) a definite dysfunction on at least one 1 
sensory dimension (all domains except social participation) and the total score on the 2 
Sensory Processing Measure (SPM)(17) or (b) at least a probable dysfunction on two or more 3 
sensory dimensions and the total score; 4 
v. provide carer consent/child assent. 5 
 6 
Other than the obverse of the inclusion criteria, participants will be excluded if:  7 
i. Currently undergoing or previously undergone SIT 8 
ii. Currently undergoing an intensive, comprehensive Applied Behaviour Analysis-based 9 
intervention. 10 
 11 
Recruitment process 12 
Participants will be recruited from Child and Adolescent mental Health Services 13 
(CAMHS)/paediatrics, occupational therapy, schools and support/social services. The study will also 14 
be advertised on relevant websites (i.e. related charities’ websites) and via social media and trial 15 
specific website. It will also be possible for carers to make a self-referral. 16 
 17 
Informed consent 18 
Potential participants will have a range of impairments and some may have a degree of intellectual 19 
disability. No child will be excluded on this basis, or due to other co-morbid conditions, provided all 20 
other inclusion criteria are met and exclusion criteria not met. Informed consent from carers and 21 
assent from children will be sought. The child’s school may be asked for feedback on the child’s 22 
behaviour and will be asked to complete the Aberrant Behaviour Checklist – Irritability scale (ABC-I) 23 
at 6 months.  24 
Video recording: Assessment of fidelity and mentoring require sessions to be video recorded. 25 
Permission to video record the Autism Diagnostic Observation Schedule (ADOS)(18) will also be 26 
8 
 
sought.  Eligibility to participate in the trial is not however contingent on provision of consent to 1 
video record.  2 
 3 
Randomisation and blinding 4 
Participants are assigned an identification number at consent. These are allocated sequentially for 5 
each site. Following screening, consent and collection of baseline data, participants will be randomly 6 
allocated to usual care or SIT in a 1:1 ratio. Online randomisation will be carried out by the research 7 
team and will utilise minimisation with a random component used to allocate participants to the 8 
group that causes the least imbalance.  Allocations will be minimised by site, severity of sensory 9 
processing difficulty, and sex of the child.  10 
It will not be possible to blind recruiters to previous allocations. All data cleaning and manipulation 11 
prior to statistical analysis will be carried out blind to allocated treatment.  12 
 13 
Outcome measures 14 
Primary outcome measures 15 
The primary outcome, to be measured at baseline, six and 12 months post-randomisation (Fig. 1.) is 16 
irritability/agitation as measured by the corresponding Aberrant Behaviour Checklist sub-scale 17 
(Community version ABC-I: 15 items(13)(14)). This scale is completed by the parent/carer. The 18 
primary outcome time point is at six months post-randomisation (i.e. immediately post-intervention 19 
in the SIT arm). Teacher/teaching assistant ratings of ABC-I (assessed at six months post-20 
randomisation only) will be measured to explore agreement between teacher and carer assessments 21 
and as way of measuring carer response bias. 22 
 23 
Secondary outcome measures 24 
All secondary outcomes will be measured at baseline, six and 12 months post-randomisation (Fig. 25 
1.). These are all completed by the parent/carer. 26 
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Other problem behaviours will be measured using the remaining four ABC sub-scales(13)(19)(20).  1 
Adaptive behaviours, socialisation and functional skills change will be assessed using the Vineland 2 
Adaptive Behaviour Scales (VABS-II: parent/carer rating version(21)).  3 
Carer stress will be assessed using the Autism Parenting Stress Index (APSI(22)). 4 
Carer Quality of Life will be measured using two measures the EQ5D 5L(23) scale and CarerQol(24).  5 
 6 
Mediators  7 
Scores on the SPM(17) will be assessed at screening and six months post-randomisation in order to 8 
determine whether any effects of the intervention on the primary outcome at 12 months (if 9 
observed) are mediated by severity of SP difficulty post-intervention.  10 
 11 
Health Economics measures 12 
Detailed information on staff and non-staff inputs directly associated with the SIT intervention and 13 
UC will be recorded for each participant during the intervention period. Data on services and 14 
support external to the intervention will be collected at interview for each participant in the study at 15 
baseline (covering the previous 6 months), six, and 12 months post-randomisation. The Client 16 
Service Receipt Inventory (CSRI)(25) will be adapted for use in this study to not only collect service 17 
and support data for the child but also data on health and social care services used by the child’s 18 
main carer. This will include carer out-of-pocket expenses and time taken off work to care for their 19 
child. 20 
 21 
Screening measure 22 
The SPM(17) is included at screening to confirm definite/probable sensory processing difficulties 23 
(Fig. 2.). The measure provides norm-referenced standard scores for seven domains: visual, auditory, 24 
tactile, proprioceptive, vestibular, praxis, social participation; and a total sensory systems score. 25 
Scores then fall into one of three interpretive ranges: Typical, Some Problems or Definite 26 
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Dysfunction. For the purposes of the current trial, sensory processing difficulty is defined as either: 1 
(a) a definite dysfunction on at least one sensory dimension (defined as all domains except social 2 
participation) and the total score or (b) at least a probable dysfunction on two or more sensory 3 
dimensions and the total score. Treating therapists will access these scores in order to aid with 4 
delivery of the intervention. 5 
 6 
Baseline measure 7 
To characterise the recruited sample according to ASD symptoms, the ADOS will be included as a 8 
baseline measure. ADOS administrators will be trained to research standard and assessments will be 9 
video recorded. A sample of these recordings will then be used to ensure consistency in 10 
administration and coding between researchers.  11 
 12 
Data management 13 
All assessments will be completed using web-based Case Report Forms (CRFs). This is a secure 14 
encrypted system accessed by username and password. All data will be stored in accordance with 15 
the General Data Protection Regulation 2016. In the event that the web-based system is not 16 
accessible, paper CRFs will be used to record data. The data will then be inputted into the web-based 17 
system once it is accessible. A full data management plan detailing cleaning and quality control will 18 
accompany the protocol. We will make every effort to reduce loss to follow-up using strategies also 19 
outlined in the data management plan. 20 
 21 
Sensory Integration Therapy 22 
Those allocated to the intervention arm will receive 26 one-hour sessions of SIT(26)(27), delivered 23 
over 26 weeks: two sessions per week for 10 weeks (intensive phase), followed by two sessions per 24 
month for two months, then one telephone session per month for two months (tailoring phase). A 25 
detailed assessment (SIT arm only) of sensory processing deficit will be undertaken (Sensory 26 
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Integration and Praxis Tests: SIPT(28)) along with clinical observations post-randomisation. Following 1 
this assessment, the data will be scored to generate a SIPT report and a hypothesis developed as to 2 
the nature of the underlying sensory difficulty affecting function. In addition, background history, 3 
and the Canadian Occupational Performance Measure (COPM)(29) will be carried out. SIT uses the 4 
‘just right’ challenge – a key principle of the sensory integrative approach – for each child and is 5 
therefore able to adjust the therapy to functional ability (as measured at baseline). Carers will be 6 
encouraged to observe or actively participate in sessions to facilitate engagement. Between 7 
sessions, carers may be given brief written guidelines of specific sensory-motor activities to support 8 
their child’s sensory integration. Success of these strategies will be discussed at the following 9 
session.  10 
The intervention will be delivered by occupational therapists (typically NHS Band 7) trained in SIT 11 
and meeting fidelity criteria(15) in regional clinics which also meet fidelity. Initially clinics will be 12 
located in South Wales and Cornwall with the potential for more to be included based on 13 
recruitment rates and therapist availability. For the duration of the trial, each intervention therapist 14 
will be paired with a mentor - a therapist independent to their clinic who is trained in both SI and 15 
mentoring. The mentor will support the therapist in the assessment, interpretation and intervention 16 
of the child. This is a critical part of the trial process that will help provide evidence of meeting 17 
intervention fidelity criteria. Mentoring sessions will be approximately one hour long and provided 18 
ideally fortnightly during the first two months for the first participant during the intervention 19 
delivery phase, tapering to once per month or at least once every 6 weeks thereafter. A private, 20 
closed Facebook group for treating therapists to support each other will also be established. This is 21 
monitored by the research team to ensure that no personal information is included or discussed. 22 
Intervention therapists will provide therapy to participants recruited to the SIT arm only. Those 23 
participants receiving any form of usual care (such as provision of sensory strategies and/or face-to-24 
face sessions delivered once per week or less) will be seen by occupational therapists not delivering 25 
SIT in the current trial.  26 
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After the participant has entered the trial, the therapist must remain free to give alternative 1 
treatment to that specified in the protocol, at any stage, if he/she feels it to be in the best interest of 2 
the participant.  3 
 4 
Fidelity assessment 5 
Intervention delivery will be assessed using the Ayres Sensory Integration® Intervention Fidelity 6 
Measure(15). The first two video recorded face-face sessions delivered to any participant for each 7 
therapist will be assessed purely to address any training issues at the earliest opportunity and to 8 
ensure ongoing fidelity can be rated.  A sample of recorded sessions in the intensive phase will then 9 
be rated for fidelity by an independent SIT-trained therapist. Demonstration of adequate fidelity is 10 
defined as scoring 80/100 or above on the fidelity measure(15) across at least 80% of sessions 11 
sampled. An ‘effective’ dose for SIT has not yet been established however, based on clinical 12 
experience and currently available evidence(7)(9)(10)(11) attending 13 of a possible 20 sessions 13 
delivered during the intensive intervention phase (two thirds) is likely to indicate sufficient exposure. 14 
Structural fidelity is assessed according to level of therapist training/qualifications, followed by a 15 
score of 85/110 for four areas: safety of the environment, detail and content of therapist-held 16 
records including therapist-carer collaboration in relation to goals set during therapy, physical space 17 
and equipment, and communication with carers.  18 
We plan to identify suitable additional resources to use the video recording to look into fidelity of 19 
delivery in more detail. As part of this, we will include specific items to gauge the impact of non-20 
specific therapist effects, using an adapted version of a tool developed for evaluation of psychosocial 21 
interventions for individuals with intellectual disability(30)(31).  22 
 23 
Comparator 24 
Usual Care (UC) will be recorded by carers in diary format. The current standard care pathway is 25 
variable across the UK, ranging from minimal contact/no specific treatment targeted at sensory 26 
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processing, to provision of manualised SIT in some regions. However, within the proposed trial sites, 1 
we estimate that usual care will be much less intensive than the 26-week programme detailed 2 
above, ranging from some provision of sensory strategies not meeting full fidelity criteria for SIT (and 3 
should not occur more frequently than once per week) to no specific treatment. Notes will be kept 4 
according to usual policy. Usual care for ASD will also be recorded more generally including any 5 
contact with NHS services (e.g. speech therapy, paediatrics and CAMHS).  6 
Usual care for the current trial will be assessed and fully defined following a brief pre-recruitment 7 
survey of therapists, and discussions (e.g. as interviews or focus groups) with carers and 8 
occupational therapists. The potential for contamination, if participants recruited to the UC arm 9 
receive enhanced/additional support from clinicians who are aware of their participation in the trial 10 
is acknowledged, thus there will be an examination as to whether the UC received differs in any way 11 
from the provision mapped out as a result of the scoping focus groups. 12 
 13 
Internal pilot and progression criteria for full trial 14 
An initial internal pilot phase will assess feasibility of recruitment, retention to the intervention and 15 
the nature of UC for sensory processing difficulties in the control arm.  16 
Progression criteria are as follows:  17 
1. Recruitment feasibility criteria will be met if at least 70% of those approached 18 
meet eligibility criteria for trial entry and at least 50% of those eligible are willing 19 
to be randomised. The proposed internal pilot end date is study month 18. 20 
Overall recruitment rates will be formally reviewed at this time point. 21 
2. Once approximately 10% of participants have completed the post-22 
intervention/six-month follow-up, carer-completed diaries will be qualitatively 23 
assessed to determine whether UC is sufficiently different from the SIT 24 
intervention for the full trial to continue. Broadly defined, this criterion will be 25 
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met provided those in the UC arm do not receive any intervention meeting 1 
criteria for full SIT. 2 
3. If dropout at the six-month post-randomisation time point exceeds 20%, the 3 
sample size calculation and associated implications for feasibility of recruitment 4 
will be re-assessed.  5 
4. To confirm the accuracy of the sample size calculation and other features of the 6 
proposed design, an estimate of the following will be obtained: (a) proportion of 7 
participants providing primary outcome data; (b) SD of the ABC-I at the primary 8 
outcome time point (post-intervention) in both SIT and UC groups; (c) intra-9 
cluster correlation coefficient (ICC) of SIT therapists within participants for the 10 
ABC-I at the primary outcome time point (post-intervention, SIT arm only); (d) 11 
correlation between baseline and six-month post-randomisation ABC-I. Sample 12 
size may be adjusted following these explorations. 13 
 14 
Collection of Usual Care data 15 
A minimum of two scoping focus groups will be held prior to recruitment. Each will utilise a case 16 
analysis approach with clinicians providing treatment for sensory processing difficulties (one in each 17 
region). A small number of one-to-one telephone interviews may supplement focus group data as 18 
required. Focus groups will explore what is currently delivered/received as UC in the Health 19 
Boards/Trusts involved, and what if any difference exists in local provision and between regions (i.e. 20 
currently South Wales and England).  21 
To develop a schedule for the focus groups, a brief survey will have been distributed to Occupational 22 
Therapist Practice leads (OTs) in trial regions working with the trial population, via OT service leads.  23 
Interviews with carers of children with ASD and sensory processing difficulties (parents from both 24 
South Wales and Cornwall) will be conducted. These will utilise a time-line facilitated process(31). 25 
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We will ask participants to focus on key points along a timeline, including ‘the beginning’, ‘diagnosis’ 1 
and ‘now’.   2 
 3 
Family carer and therapist interviews 4 
Following the six-month/post-intervention time-point, interviews will be conducted with all SIT 5 
therapists (5-10 interviews) and a sample of family carers in both arms (anticipated to be 10-15 in 6 
each arm before data saturation).  7 
Primary carers may choose to be interviewed alone or with other members of their family who are 8 
involved in day-to-day care.  Participants will be asked to reflect on their experience of the 9 
intervention and the usual care activities that occurred alongside it, or their experience of usual care 10 
alone.   11 
Therapists will be sampled to achieve variation in Health Board/Trust and regional centre and will be 12 
given the choice of telephone or face-to-face interviews. Family carers will be sampled to ensure 13 
maximum variation in terms of range of ASD and sensory symptoms, Health Board/Trust, and 14 
regional centre. Interviews will take place at a location of the interviewee’s choice, often their home, 15 
or over the phone.  16 
The interview topic guides will be developed from a review of previous research, guides used by the 17 
research team in similar studies, and with input from the multi-disciplinary research team and family 18 
carer advisors to avoid bias in topic selection and wording of questions. The topic guide will be 19 
piloted and refined as necessary. Interviews will be recorded and transcribed.  20 
 21 
Safety reporting 22 
No adverse events are expected. However, adverse events will be collected, recorded and reported 23 
in accordance with Good Clinical Practice and the requirements of the research ethics committee. 24 
The Chief Investigator may carry out Urgent Safety Measures if appropriate to protect participants 25 
from immediate harm. 26 
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 1 
Sample size determination 2 
We will recruit 216 participants in total (108 allocated to usual care, 108 allocated to the SIT 3 
intervention). This will provide 90% power at the 5% significance level (two-sided) to detect a 4 
standardised effect size of 0.5, allowing for 20% loss to follow-up at primary outcome time point (six-5 
months post-randomisation).  6 
Our effect size is based on means and standard deviations of the ABC-I in relevant populations found 7 
in the literature(19)(32)(33). This literature also suggests that a 25% relative difference represents a 8 
clinically meaningful difference on the ABC-I. Findings from the internal pilot will aid in confirming 9 
the accuracy of the assumptions behind the sample size calculation and could potentially lead to an 10 
adjustment of this. 11 
 12 
Main analysis 13 
The primary analysis will be based on the Modified Intention To Treat (MITT) analysis population, 14 
and will estimate the between-group mean difference in the ABC-I at six months using linear 15 
regression, adjusting for baseline ABC-I, recruitment site, severity of SP difficulty, and sex of the 16 
child. If appropriate, therapist clustering will be accounted for using mixed models. Secondary 17 
outcomes will be analysed similarly. 18 
 19 
Sub-group analysis  20 
Subgroup analyses will be conducted, exploring any differential intervention effects by site, region, 21 
age, sex of the child, severity of SP difficulties, adaptive behaviour, socialisation, motor skills and 22 
comorbid conditions. This will be carried out by repeating the primary analysis but including each 23 
subgroup as an explanatory variable along with a subgroup x treatment arm interaction. Subgroup 24 
analyses will also be performed carer stress. 25 
 26 
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Impact of missing data and non-adherence 1 
The impact that non-adherence to the intervention has on the Intention To Treat (ITT) findings will 2 
be investigated by estimating the Complier-Average Causal Effect (CACE) for the primary and 3 
secondary outcomes(34).  4 
While the main trial analysis will be based on a MITT analysis population, sensitivity analyses will be 5 
carried out exploring the impact that missing data may have had on trial findings. Where outcome 6 
data are missing due to drop-out/loss to follow-up, these will be assumed to be missing at random 7 
given observed data (MAR), and multiple imputation will be used to achieve a full ITT analysis 8 
population. Additional sensitivity analyses will be conducted using joint modelling approaches (e.g. 9 
selection and/or pattern mixture models) to explore departures from a MAR assumption(35).  10 
 11 
Mediation analysis  12 
Exploratory mediation analyses will be conducted to examine whether any effect of the intervention 13 
on behavioural problems at one-year (all ABC subscales) is mediated through an effect on sensory 14 
sensitivities immediately post-intervention. The analyses will control for baseline measures of 15 
behavioural problems and SP difficulties, to minimise any residual confounding between mediator 16 
and outcome(36). Additional analyses will be conducted to explore the association between 17 
measures collected as part of the process evaluation and primary/key secondary outcomes. As the 18 
majority of process evaluation measures will only be collected for participants allocated to the SIT 19 
arm, the analysis will be purely associational and therefore hypothesis generating in nature.  20 
 21 
Exploratory analysis 22 
Given the variability in the ‘usual care’ that we are likely to see, we will conduct analyses using 23 
participants in the UC arm only that explore the association between different types of usual care 24 
and clinical outcomes. Parameters we will use to characterise different types of usual care will 25 
include number of treatment contacts, therapist experience/level of training, and type of difficulty 26 
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for which the therapy is intended. Regression models will be fitted using our primary and secondary 1 
outcomes, and the therapy characteristics/parameters as explanatory variables. Variables that 2 
confound the relationship between therapy characteristics and outcome (e.g. age, severity of SP 3 
difficulty) will be investigated and controlled for in the models. The interpretation of the findings 4 
from these analyses will reflect the exploratory nature of this work and will be purely associational 5 
(that is, without ascribing cause). 6 
A Statistical Analysis Plan will provide further detail on analytical methods using for the analysis of 7 
trial outcomes, and will be finalised prior to the end of recruitment. 8 
 9 
Qualitative analysis 10 
Qualitative data will be analysed by the qualitative team using thematic analysis(37). We will search 11 
across the data set to find repeated patterns of meaning, and identify key themes and sub-themes. 12 
We will identify contradictory data, as points of contrast as well as similarities to understand uptake 13 
and engagement with the intervention. Vital measures will be put into place to ensure validity and 14 
reliability. Double coding will be carried out until consensus is reached. Data will be managed using 15 
qualitative coding software (such as NVivo10). This qualitative component has been designed using 16 
the principles of the Critical Appraisal Skills Programme qualitative checklist, to ensure the quality of 17 
qualitative research(38).  18 
 19 
Health economic analysis 20 
A within trial health economic analysis will be conducted from a health and personal social services 21 
(NHS and PSS) perspective. The health economic analysis will be carried out on an ITT basis. The 22 
main analyses will compare cost and cost-effectiveness at six-months follow-up of SIT compared to 23 
UC. Total and mean costs for the SIT and UC group will be reported in a disaggregated format. Total 24 
and mean severity outcomes (ABC-I) will be reported for the intervention and control groups. The 25 
difference in mean scores between the two groups will be assessed with appropriate statistical tests. 26 
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The difference in mean costs for the treatment groups will be analysed using regression analysis and 1 
bootstrapping. NHS and PSS costs (or societal costs in the secondary analyses) over the six-months 2 
will be regressed on treatment allocation, baseline ABC-I, site, severity of SP difficulty and baseline 3 
costs. We will account for clustering in the analysis.  4 
Incremental cost-effectiveness ratio (ICER) will be calculated, defined as the difference in mean costs 5 
divided by difference in mean ABC-I as: a) the incremental cost per participant achieving a significant 6 
improvement in mean ABC-I score from an NHS/PSS perspective. Results will be plotted on a cost-7 
effectiveness plane. Bootstrapping will be used to estimate a distribution around costs and 8 
behavioural outcomes and to estimate the confidence intervals around the incremental cost-9 
effectiveness ratio Cost-effectiveness acceptability curves (CEAC), a recommended decision-making 10 
approach to dealing with uncertainty, will be generated by plotting these probabilities for a range of 11 
values of the ceiling ratio. Sensitivity analysis will be used to explore the sensitivity of the results 12 
from using a broader societal perspective (including NHS/PSS costs, education service costs, carer 13 
expenses and lost productivity) than a narrower NHS/PSS perspective preferred by the National 14 
Institute for Health and Care Excellence (NICE) reference case(39). Additional sensitivity analyses will 15 
build on results of the subgroup analyses.  16 
 17 
Trial management 18 
A Trial Management Group (TMG) will meet 4-6 weekly and will include all Investigators and the trial 19 
Project Team to discuss trial progression and key management issues. An Independent Data 20 
Monitoring Committee (IDMC) and Trial Steering Committee (TSC) will also be convened and will 21 
meet annually. The IDMC will comprise of a statistician as an independent chair and 2 other experts 22 
in the field. The IDMC will monitor data and make recommendations to the  TSC  on  whether  there  23 
are  any  ethical  or  safety  reasons  why  the  trial should not continue. The TSC will comprise of an 24 
independent Chair with expertise in trials of occupational therapy, an independent ASD expert, an 25 
independent statistician and a health economist. The Co-CIs, Statistician and Trial Manager will be 26 
20 
 
observers at each group. The TSC will provide overall supervision for the trial and provide advice 1 
through its independent chair and will advise NIHR whether the trial should continue following the 2 
results of the internal pilot. TSC and IDMC members will be required to sign up to the remit and 3 
conditions set out in a Charter. 4 
 5 
Quality control and assurance 6 
A clinical trial risk assessment has been used to determine the intensity and focus of central and on-7 
site monitoring activity. Low monitoring levels will be employed and fully documented in the trial 8 
monitoring plan. 9 
Investigators should agree to allow trial related monitoring, including audits and regulatory 10 
inspections, by providing direct access to source data/documents as required. Participant consent 11 
for this will be obtained. Findings generated from on-site and central monitoring will be shared with 12 
the Sponsor, CI, PI & local R&D. 13 
 14 
Audits & inspections 15 
The trial is participant to inspection by the Health Technology Assessment programme (HTA) as the 16 
funding organisation. The trial may also be participant to inspection and audit by Cardiff University 17 
under their remit as Sponsor. 18 
 19 
Dissemination 20 
All publications and presentations relating to the trial will be detailed in the publication policy which 21 
will be drafted and authorised by the TMG. 22 
 23 
Discussion 24 
This trial will address the question ‘What is the clinical and cost-effectiveness of sensory integration 25 
therapy for children with autism spectrum disorder?’ As part of this unique trial design, we will also 26 
21 
 
be including monitoring to ensure fidelity of intervention delivery as well as supervision/mentoring 1 
for therapist support. We believe this research will benefit the NHS in terms of providing clear 2 
evidence regarding the clinical effectiveness and cost-effectiveness of this type of intervention 3 
thereby informing clinical practice for this population. We also strongly believe that children and 4 
their families will benefit from receiving treatment informed by a more robust evidence base, 5 
whether or not SIT itself is effective. Furthermore, if SIT is effective, the proposed intervention could 6 
improve behavioural, functional, social, educational and well-being outcomes for children and well-7 
being outcomes for family carers. Subgroup analyses will also help to determine which children and 8 
families would be most likely to benefit, thereby maximising cost-effective roll-out. 9 
 10 
Trial status 11 
The trial is sponsored by Cardiff University (Research and Innovation Services, 12 
RIScentraloperations@cardiff.ac.uk) and is currently on-going and open to follow-up. Recruitment 13 
commenced in July 2017 and is anticipated to end in Spring 2019. This manuscript has been drafted 14 
according to version 5.0 (11.04.2018) of the trial protocol. The protocol has been written according 15 
to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement 16 
(Additional File 1); the intervention according to the TIDieR (template for intervention description 17 
and replication) checklist; and the final report will follow the CONSORT (Consolidated Standards of 18 
Reporting Trials) statement. 19 
 20 
List of abbreviations 21 
ABC Aberrant Behaviour Checklist 22 
ABC-I Aberrant Behaviour Checklist irritability scale 23 
ADOS Autism Diagnostic Observation Schedule 24 
APSI Autism Parenting Stress Index 25 
ASD Autism Spectrum Disorder 26 
22 
 
CACE Complier-average Causal Effect 1 
CAMHS Child and Adolescent Mental Health Services 2 
CARERQoL Carer Quality of Life 3 
CEAC Cost-effectiveness acceptability curves 4 
CONSORT Consolidated Standards of Reporting Trials 5 
COPM Canadian Occupational Performance Measure 6 
CRF Case Report Form 7 
CSRI Client Service Receipt Inventory 8 
EQ5D EuroQol 5D 9 
ICC Intraclass Correlation Coefficient 10 
ICER Incremental Cost-effectiveness Ratio 11 
ISRCTN International Standard Randomised Controlled Trial Number 12 
ITT Intention to Treat 13 
MAR Missing at Random 14 
MITT Modified Intention to Treat 15 
MRC Medical Research Council  16 
NHS National Health Service 17 
NICE National Institute for Clinical Excellence 18 
OT Occupational Therapy 19 
PSS Personal Social Services 20 
QoL Quality of Life 21 
RCT Randomised Controlled Trial 22 
SBI Sensory Based Intervention 23 
SD Standard Deviation 24 
SIPT Sensory Integration Praxis Test 25 
SIT Sensory Integration Therapy 26 
23 
 
SP Sensory Processing 1 
SPM Sensory Processing Measure 2 
SPIRIT Standard Protocol Items: Recommendations for Interventional Trials 3 
TIDieR Template for intervention description and replication 4 
UC Usual Care 5 
VABS Vineland Adaptive Behaviour Scale 6 
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